Recent studies have reported a small sample of EGFRm NSCLC patients in stage IIIB receiving salvage surgery following EGFR-TKI treatment and demonstrated the feasibility of neoadjuvant EGFR-TKI therapy for EGFRm NSCLC in stage IIIB (12, 13). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.